James L. Speyer

5.6k total citations
94 papers, 4.4k citations indexed

About

James L. Speyer is a scholar working on Oncology, Reproductive Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, James L. Speyer has authored 94 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 23 papers in Reproductive Medicine and 22 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in James L. Speyer's work include Cancer Treatment and Pharmacology (35 papers), Ovarian cancer diagnosis and treatment (23 papers) and Chemotherapy-induced cardiotoxicity and mitigation (22 papers). James L. Speyer is often cited by papers focused on Cancer Treatment and Pharmacology (35 papers), Ovarian cancer diagnosis and treatment (23 papers) and Chemotherapy-induced cardiotoxicity and mitigation (22 papers). James L. Speyer collaborates with scholars based in United States, Australia and Italy. James L. Speyer's co-authors include Charles E. Myers, Jerry M. Collins, Howard S. Höchster, Jean Jenkins, Franco M. Muggia, Robert L. Dedrick, Raymond F. Greene, Anne Zeleniuch‐Jacquotte, J Wernz and Paul H. Sugarbaker and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

James L. Speyer

93 papers receiving 4.2k citations

Peers

James L. Speyer
Christopher Poole United Kingdom
Saul E. Rivkin United States
P Dombernowsky Denmark
A.T. van Oosterom Netherlands
Peter Canney United Kingdom
Patrizia Vici Italy
Jacob J. Lokich United States
Jörg T. Hartmann Germany
N. Colombo Italy
J.T. Thigpen United States
Christopher Poole United Kingdom
James L. Speyer
Citations per year, relative to James L. Speyer James L. Speyer (= 1×) peers Christopher Poole

Countries citing papers authored by James L. Speyer

Since Specialization
Citations

This map shows the geographic impact of James L. Speyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James L. Speyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James L. Speyer more than expected).

Fields of papers citing papers by James L. Speyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James L. Speyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James L. Speyer. The network helps show where James L. Speyer may publish in the future.

Co-authorship network of co-authors of James L. Speyer

This figure shows the co-authorship network connecting the top 25 collaborators of James L. Speyer. A scholar is included among the top collaborators of James L. Speyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James L. Speyer. James L. Speyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Novik, Yelena, Adrian A. Franke, Karina Martínez‐Flores, et al.. (2025). Evaluation of the gut microbiome and sex hormones in postmenopausal women with newly diagnosed hormone receptor-positive breast cancer versus healthy women: a prospective case-control study. Journal of Cancer Research and Clinical Oncology. 151(10). 275–275. 1 indexed citations
2.
Novik, Yelena, Maryann Kwa, James L. Speyer, et al.. (2020). 129P Phase II study of pembrolizumab and nab-paclitaxel in HER2-negative metastatic breast cancer: Hormone receptor-positive cohort. Annals of Oncology. 31. S59–S59. 2 indexed citations
3.
Kwa, Maryann, Xiaochun Li, Yelena Novik, et al.. (2017). Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer. Breast Cancer Research and Treatment. 168(1). 57–67. 18 indexed citations
4.
Adams, Sylvia, Lina Kozhaya, Frank Martiniuk, et al.. (2012). Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer. Clinical Cancer Research. 18(24). 6748–6757. 184 indexed citations
5.
Höchster, Howard S., Elizabeth R. Plimack, John Mandeli, et al.. (2005). Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: An NYGOG and ECOG study. Gynecologic Oncology. 100(2). 324–329. 8 indexed citations
6.
Rosenberg, Elizabeth, Rita I. Demopoulos, Anne Zeleniuch‐Jacquotte, et al.. (2001). Expression of cell cycle regulators p57KIP2, cyclin D1, and cyclin E in epithelial ovarian tumors and survival. Human Pathology. 32(8). 808–813. 56 indexed citations
7.
8.
Rosenthal, Mark, David T. Dennis, Leonard Liebes, et al.. (1998). Biologic Activity of Interleukin 1 (IL-1) Alpha in Patients with Refractory Malignancies. Journal of Immunotherapy. 21(5). 371–378. 4 indexed citations
9.
Höchster, Howard S., Leonard Liebes, James L. Speyer, et al.. (1997). Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.. PubMed. 3(8). 1245–52. 49 indexed citations
10.
Swain, Sandra M., Fredrick S. Whaley, Stuart P. Weisberg, et al.. (1997). Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.. Journal of Clinical Oncology. 15(4). 1318–1332. 466 indexed citations
11.
Höchster, Howard S., Carolyn Wasserheit, & James L. Speyer. (1995). Cardiotoxicity and cardioprotection during chemotherapy. Current Opinion in Oncology. 7(4). 304–309. 45 indexed citations
12.
Speyer, James L., John Mandeli, Howard S. Höchster, et al.. (1995). A Phase I Trial of Cyclosphosphamide and Carboplatinum Combined with Interleukin-3 in Women with Advanced-Stage Ovarian Cancer. Gynecologic Oncology. 56(3). 387–394. 8 indexed citations
13.
Blum, Ronald H., et al.. (1992). Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor. Journal of Cancer Research and Clinical Oncology. 118(1). 61–66. 6 indexed citations
14.
Muggia, Franco M., Kenneth K. Chan, Christy Russell, et al.. (1991). Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2′-deoxyuridine. Cancer Chemotherapy and Pharmacology. 28(4). 241–250. 20 indexed citations
15.
Beller, Uziel, James L. Speyer, Nicoletta Colombo, et al.. (1991). Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.. Journal of Clinical Oncology. 9(5). 809–817. 11 indexed citations
16.
Höchster, Howard S., Michael Green, Leonard Liebes, et al.. (1990). Good tolerance of weekly oral idarubicin: (4-demethoxydaunorubicin): A phase I study with pharmacology. Cancer Chemotherapy and Pharmacology. 26(4). 297–300. 9 indexed citations
17.
Kirkwood, John M., Marc S. Ernstoff, A. E. Giuliano, et al.. (1990). Interferon α-2a and Dacarbazine in Melanoma. JNCI Journal of the National Cancer Institute. 82(12). 1062–1063. 32 indexed citations
18.
Green, Michael D., et al.. (1990). Phase II study of esorubicin (4 ′ deoxydoxorubicin) in anthracycline naive patients with ovarian cancer. Investigational New Drugs. 8(3). 333–336. 1 indexed citations
19.
Speyer, James L., Uziel Beller, Nicoletta Colombo, et al.. (1990). Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.. Journal of Clinical Oncology. 8(8). 1335–1341. 65 indexed citations
20.
Speyer, James L., Joseph J. Sanger, Anne Zeleniuch‐Jacquotte, et al.. (1990). A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer. Cancer Treatment Reviews. 17(2-3). 161–163. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christopher Poole Breakdown of academic impact, for papers by Saul E. Rivkin Breakdown of academic impact, for papers by P Dombernowsky Breakdown of academic impact, for papers by A.T. van Oosterom Breakdown of academic impact, for papers by Peter Canney Breakdown of academic impact, for papers by Patrizia Vici Breakdown of academic impact, for papers by Jacob J. Lokich Breakdown of academic impact, for papers by Jörg T. Hartmann Breakdown of academic impact, for papers by N. Colombo Breakdown of academic impact, for papers by J.T. Thigpen
Rankless by CCL
2026